2020年歐洲腫瘤內科學會(ESMO)年會將于9月14日-10月18日在線上召開，其中9月19日-21日的science weekend將有眾多腫瘤領域新數據公布。作為歐洲最負盛名及最具影響力的腫瘤學會議，本次會議將展示腫瘤學的最新進展，搭建學術研究與臨床實踐溝通的橋梁。 作為中
2020年歐洲腫瘤內科學會(ESMO)年會將于9月14日-10月18日在線上召開，其中9月19日-21日的science weekend將有眾多腫瘤領域新數據公布。作為歐洲最負盛名及最具影響力的腫瘤學會議，本次會議將展示腫瘤學的最新進展，搭建學術研究與臨床實踐溝通的橋梁。
作為中國創新藥物研發的先行者與領跑者，恒瑞醫藥多款研發藥物再次登錄國際舞臺，治療領域涵蓋消化道腫瘤、肺癌、骨肉瘤、乳腺癌、頭頸部腫瘤、血液腫瘤、婦科腫瘤等多個領域。
今天，先讓我們一睹為快，看看有哪些研究即將亮相！
ACTIVE: Apatinib plus gefitinib versus placebo plus gefitinib as first-line treatment for advanced non-squamous non-small-cell lung cancer patients with activating EGFR mutations: a multicentered, randomized,double-blind,placebo-controlled phase IIItrial (CTONG1706)
甲磺酸阿帕替尼一線聯合吉非替尼治療晚期EGFR 突變NSCLC 的III期臨床研究
1267P - Efficacy of camrelizumab (SHR-1210) plus apatinib as second-line treatment for advanced squamous NSCLC
卡瑞利珠單抗聯合阿帕替尼二線治療晚期鱗狀NSCLC
報告形式：E-Poster
講者：Guanghui Gao(Shanghai,China)
1366P - Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance (date updated)
阿帕替尼聯合EGFR-TKI治療EGFR-TKI耐藥后的晚期NSCLC(數據更新)
講者：Ruifen Tian(Taiyuan, China)
1804P - The Efficacy of Apatinib plus Topotecan as Laterline Therapy for Advanced Small Cell Lung Cancer
阿帕替尼聯合拓撲替康作為晚期小細胞肺癌后線治療療效
講者：Haifeng Qin(Beijing, China)
1805P - Apatinib combined with irinotecan in the treatment of small cell lung cancer: a phase 2, single-arm, prospective study
阿帕替尼聯合伊立替康治療小細胞肺癌：II期、單臂、前瞻性研究
講者：Yanbin Zhao(Harbin, China)
983P-Camrelizumab(C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (RESCUE): an open-label, multi-center, phase 2 trial.
卡瑞利珠單抗聯合阿帕替尼治療晚期肝細胞癌(RESCUE)：開放標簽、多中心、II期研究
講者：Jianming Xu(Beijing, China)
985P - A phase 2 study of camrelizumab for advanced hepatocellular carcinoma: two-year outcomes and continued treatment beyond RECIST-defined progression.
卡瑞利珠單抗治療晚期肝細胞癌的II期研究：RECIST定義進展后持續治療2 年結果
講者：Zhenggang Ren(Shanghai, China)
81TiP - The changes of immune function and prognosis in advanced perihilar cholangiocarcinoma patients by immunotherapy combined with different topical therapies
免疫療法聯合其他類型治療晚期肝門型膽管細胞癌患者的免疫功能及預后改變
講者：Chao Zhao(Taiyuan,China)
1452P - Phase I study of apatinib plus POF (paclitaxel plus FOLFOX) in patients (pts) with treatment-na?ve advanced gastric cancer (TNAGC), the result including the dose level (dl) at 850mg
阿帕替尼聯合POF( 紫杉醇+FOLFOX) 治療初治晚期胃癌患者(TNAGC) 的I 期研究，包含850mg 劑量的結果
講者：Rongbo Lin(Fuzhou, Fujian, China)
1455P - A single-arm, open-label, prospective, multicenter study of apatinib combined with chemotherapy as second-line therapy in patients with advanced gastric cancer
阿帕替尼聯合化療二線治療晚期胃癌患者的單臂、開放標簽、前瞻性、多中心研究
講者：Jifeng Feng(Nanjing, China)
1428P - Apatinib combined with docetaxel in second-line treatment of advanced gastric cancer: a prospective clinical study(data updated)
阿帕替尼聯合多西他賽二線治療晚期胃癌：前瞻性臨床研究(數據更新)
講者：Mudan Yang(Taiyuan, China)
1434P - A prospective, multicenter, nonrandomized,controlled trial of Apatinib plus perioperative chemotherapy with FLOT protocol and surgery for the treatment of stage III gastric cancer
阿帕替尼聯合FLOT方案圍手術期化療及手術治療III期胃癌的前瞻性多中心非隨機對照研究
講者：Jun Zhang(Shenyang, China)
442P - Camrelizumab combined with Apatinib in the treatment of patients with advanced gastric cancer and colorectal cancer ：One-arm exploratory clinical trial
卡瑞利珠單抗聯合阿帕替尼治療晚期胃癌和結直腸癌：單臂探索性臨床研究
講者：Li Xiao(Xiamen, China)
1427P - A phase II study of neoadjuvant concurrent chemoradiotherapy with apatinib for HER-2 negative Siewert type II and III adenocarcinoma of esophagogastric junction
新輔助同步放化療聯合阿帕替尼治療Siewert II型、Ⅲ型HER2陰性胃食管交界處腺癌的II期臨床研究
講者：Qun Zhao(Shijiazhuang, China)
1431P - Study on the safety and efficacy of apatinib combined with concurrent chemoradiotherapy in the treatment of nonoperative esophageal cancer
阿帕替尼聯合同步放化療治療不可切除食管癌患者的療效和安全性
講者：Jingping Yu(Changzhou, China)
1501TiP - The changes of tumor immune microenvironment in esophageal squamous cell carcinoma patients intervened by different neoadjuvant therapies
應用不同的新輔助方案治療食管鱗癌的腫瘤免疫微環境的改變
講者：Wei Li Wang(Taiyuan, China)
1034P - Camrelizumab in the Treatment of Patients with local advanced/metastatic esophageal squamous cell carcinoma (ESCC)：a multi-center, prospective, cohort study
卡瑞利珠單抗治療局部晚期/轉移性食管鱗癌(ESCC)：多中心、前瞻性隊列研究
講者：Qun Y. Zhu(Su zhou, China)
1503TiP - A Prospective Study of Apatinib in Combination with Neoadjuvant Concurrent Chemoradiotherapy for locally Advanced Esophageal Squamous Cell Carcinoma
阿帕替尼聯合同步放化療新輔助治療局部晚期食管鱗癌的前瞻性研究
講者：Jun Wang(Shijiazhuang, China)
224P - Neoadjuvant pyrotinib plus trastuzumab, docetaxel, and carboplatin in patients with HER2-positive early breast cancer: a single-group, multicenter, phase 2 study
吡咯替尼聯合曲妥珠單抗、多西他賽、卡鉑新輔助治療HER2陽性乳腺癌患者：單臂、多中心、II期研究
講者：Zhenzhen Liu(Zhengzhou, China)
225P - Phase 2 study of pyrotinib plus albumin-bound paclitaxel and trastuzumab as neoadjuvant treatment in HER2-positive early or locally advanced breast cancer
吡咯替尼聯合白蛋白紫杉醇和曲妥珠單抗新輔助治療HER2陽性早期或局部晚期乳腺癌的II期研究
講者：Ting Luo(Chengdu, Sichuan, China)
294P - Pyrotinib and capecitabine for HER2–Positive metastatic breast cancer patients with previously untreated brain metastases: A single-group multicenter phase II study
吡咯替尼聯合卡培他濱治療既往未經治療腦轉移的HER2陽性轉移性乳腺癌患者：單臂、多中心、II期研究
講者：Min Yan(Zhengzhou, China)
270P - Apatinib added to taxanes and platinum neoadjuvant chemotherapy for patients with triple-negative and HER2-positive breast cancer: a multicenter, randomized, phase II,open-label trial
阿帕替尼聯合紫杉類和鉑類用于三陰性和HER2陽性乳腺癌的新輔助治療：多中心、隨機、II期、開放標簽研究
講者：Yunjiang J. Liu(Shijiazhuang, China)
15P - Study on the mechanism of apatinib reversing tamoxifen resistance in breast cancer
講者：Qingxia Li(Shijiazhuang, China)
A Randomized Multicentered Phase 3 Study to Evaluate Apatinib in Subjects with Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer
阿帕替尼治療局部晚期或轉移性放射性碘治療分化型甲狀腺癌：多中心隨機III期研究
912MO - A single-arm, open-label, multicenter phase 2 study of camrelizumab in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) who had progressed on ≥ 2 lines of chemotherapy: CAPTAIN study
卡瑞利珠單抗治療接受過2 線及以上化療后進展的復發/ 轉移性鼻咽癌(NPC)患者的單臂、開放標簽、多中心、Ⅱ期研究：CAPTAIN
講者：Li Zhang(Guangzhou, China)
941P - Efficacy and Safety of Apatinib Combined with Capecitabine in Patients with Advanced Nasopharyngeal Carcinoma
講者：XiuYu Cai(Guangzhou, China)
893MO - An open-label, single-center,phase II, single-arm trial of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma
卡瑞利珠單抗聯合阿帕替尼治療復發/ 難治性外周T細胞淋巴瘤的開放標簽、單中心、II期、單臂研究
講者：Yan Xie(Beijing, China)
Efficacy and safety of HHPG-19K for prophylaxis of chemotherapy-induced neutropenia in patients with lymphoma
硫培非格司亭用于化療導致粒細胞減少的淋巴瘤患者的療效和安全性
講者：Liping Su(Shanxi, China)
840P - Famitinib malate plus camrelizumab for recurrent platinum-resistant ovarian/fallopian tube/primary peritoneal cancer and advanced cervical cancer: an open-label, multicenter phase II study
法米替尼聯合卡瑞利珠單抗治療鉑類耐藥的卵巢/ 輸卵管/ 原發性腹膜癌和晚期宮頸癌：開放標簽、多中心、II期研究
講者：Lingfang Xia(Shanghai, China)
1646P - Apatinib for treatment of inoperable metastatic or locally advanced chondrosarcoma: What we can learn about the biological behavior of chondrosarcoma from a multicenter study
講者：Lu Xie(Beijing, China)
1511P - A real world study of pyrotinib in patients with HER-2 positive/mutations tumors excluding breast cancer
吡咯替尼治療HER2 陽性/ 突變腫瘤(乳腺癌除外)的真實世界研究
講者：Jun Qian(Suzhou, China)
38P - Study on human plasma concentration and
serosal permeation of oral apatinib mesylate
講者：Jian Shi(Shijiazhuang, China)
注：以上預告內容為ESMO官網截至2020/08/11的最新信息，如需詳細內容至ESMO官網查閱。
本文來源：新浪醫藥 作者：sinayiyao
免責聲明：該文章版權歸原作者所有，僅代表作者觀點，轉載目的在于傳遞更多信息，并不代表“醫藥行”認同其觀點和對其真實性負責。如涉及作品內容、版權和其他問題，請在30日內與我們聯系
客服微v信：
手機APP
移動版
2543
0
京公網安備 11010802031568號
